These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 32973816

  • 1. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L, Zou X, Chen Y, Bai X, Liang T.
    Front Immunol; 2020; 11():2076. PubMed ID: 32973816
    [Abstract] [Full Text] [Related]

  • 2. Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review.
    Huang X, Yang M, Wang L, Li L, Zhong X.
    Medicine (Baltimore); 2021 May 14; 100(19):e25795. PubMed ID: 34106616
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
    Hong AR, Yoon JH, Kim HK, Kang HC.
    Front Endocrinol (Lausanne); 2020 May 14; 11():14. PubMed ID: 32047478
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma.
    Smith-Cohn MA, Gill D, Voorhies BN, Agarwal N, Garrido-Laguna I.
    Immunotherapy; 2017 Sep 14; 9(10):797-804. PubMed ID: 28877632
    [Abstract] [Full Text] [Related]

  • 7. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017 Sep 14; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 8. Pembrolizumab-induced type 1 diabetes.
    Maia A, Soares DM, Azevedo S, Pereira T, Amaral C.
    J Oncol Pharm Pract; 2024 Sep 14; 30(6):1118-1121. PubMed ID: 38766907
    [Abstract] [Full Text] [Related]

  • 9. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
    Yilmaz M.
    J Oncol Pharm Pract; 2020 Jan 14; 26(1):236-239. PubMed ID: 30955467
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
    Xu S, Lai R, Zhao Q, Zhao P, Zhao R, Guo Z.
    Front Immunol; 2021 Jan 14; 12():794099. PubMed ID: 34950153
    [Abstract] [Full Text] [Related]

  • 12. Sintilimab-induced Alopecia Universalis in a Patient With the Anti-tumor Effect of Complete Remission After Hepatectomy.
    Wen L, Zhao J, Yang Y, Chen W, Bao Y, Zhang J, Wei T, Zhou L, Xi B, Zhang Y, Liang T.
    J Immunother; 2021 Jan 14; 46(6):232-235. PubMed ID: 37212789
    [Abstract] [Full Text] [Related]

  • 13. PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity.
    Akturk HK, Alkanani A, Zhao Z, Yu L, Michels AW.
    J Clin Endocrinol Metab; 2018 Oct 01; 103(10):3589-3592. PubMed ID: 30124874
    [Abstract] [Full Text] [Related]

  • 14. Anti-PD-1 treatment-induced immediate central diabetes insipidus: a case report.
    Yu M, Liu L, Shi P, Zhou H, Qian S, Chen K.
    Immunotherapy; 2021 Oct 01; 13(15):1255-1260. PubMed ID: 34424037
    [Abstract] [Full Text] [Related]

  • 15. A case of pembrolizumab-induced fulminant Type 1 diabetes mellitus in breast cancer.
    Tang Y, Zhao Z, Wang X, Zuo W, Zhang B, Yuan T, Fu Y.
    Immunotherapy; 2021 Apr 01; 13(6):483-489. PubMed ID: 33626915
    [Abstract] [Full Text] [Related]

  • 16. Atezolizumab-Induced Autoimmune Diabetes in a Patient With Metastatic Lung Cancer.
    Sothornwit J, Phunmanee A, Pongchaiyakul C.
    Front Endocrinol (Lausanne); 2019 Apr 01; 10():352. PubMed ID: 31244772
    [Abstract] [Full Text] [Related]

  • 17. Atezolizumab-induced type 1 diabetes mellitus in a patient with metastatic renal cell carcinoma.
    Rahman W, Conley A, Silver KD.
    BMJ Case Rep; 2020 Jul 02; 13(7):. PubMed ID: 32616532
    [Abstract] [Full Text] [Related]

  • 18. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
    Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M.
    J Hepatol; 2020 Feb 02; 72(2):307-319. PubMed ID: 31954494
    [Abstract] [Full Text] [Related]

  • 19. Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.
    Choi B, McBride A, Scott AJ.
    Am J Health Syst Pharm; 2019 Oct 15; 76(21):1749-1752. PubMed ID: 31612928
    [Abstract] [Full Text] [Related]

  • 20. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.
    de Filette JMK, Pen JJ, Decoster L, Vissers T, Bravenboer B, Van der Auwera BJ, Gorus FK, Roep BO, Aspeslagh S, Neyns B, Velkeniers B, Kharagjitsingh AV.
    Eur J Endocrinol; 2019 Sep 15; 181(3):363-374. PubMed ID: 31330498
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.